These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 28836356)

  • 1. Model-Based Discovery and Development of Biopharmaceuticals: A Case Study of Mavrilimumab.
    Wang B; Wu CY; Jin D; Vicini P; Roskos L
    CPT Pharmacometrics Syst Pharmacol; 2018 Jan; 7(1):5-15. PubMed ID: 28836356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis.
    Crotti C; Biggioggero M; Becciolini A; Agape E; Favalli EG
    Expert Opin Investig Drugs; 2019 Jul; 28(7):573-581. PubMed ID: 31208237
    [No Abstract]   [Full Text] [Related]  

  • 3. A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.
    Burmester GR; McInnes IB; Kremer J; Miranda P; Korkosz M; Vencovsky J; Rubbert-Roth A; Mysler E; Sleeman MA; Godwood A; Sinibaldi D; Guo X; White WI; Wang B; Wu CY; Ryan PC; Close D; Weinblatt ME;
    Ann Rheum Dis; 2017 Jun; 76(6):1020-1030. PubMed ID: 28213566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis.
    Guo X; Higgs BW; Bay-Jensen AC; Wu Y; Karsdal MA; Kuziora M; Godwood A; Close D; Ryan PC; Roskos LK; White WI
    Rheumatology (Oxford); 2018 Jan; 57(1):175-184. PubMed ID: 29069507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting GM-CSF in rheumatoid arthritis.
    Avci AB; Feist E; Burmester GR
    Clin Exp Rheumatol; 2016; 34(4 Suppl 98):39-44. PubMed ID: 27586802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: relevance for human safety.
    Ryan PC; Sleeman MA; Rebelatto M; Wang B; Lu H; Chen X; Wu CY; Hinrichs MJ; Roskos L; Towers H; McKeever K; Dixit R
    Toxicol Appl Pharmacol; 2014 Sep; 279(2):230-9. PubMed ID: 24937321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study.
    Burmester GR; Feist E; Sleeman MA; Wang B; White B; Magrini F
    Ann Rheum Dis; 2011 Sep; 70(9):1542-9. PubMed ID: 21613310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.
    Weinblatt ME; McInnes IB; Kremer JM; Miranda P; Vencovsky J; Guo X; White WI; Ryan PC; Godwood A; Albulescu M; Close D; Burmester GR
    Arthritis Rheumatol; 2018 Jan; 70(1):49-59. PubMed ID: 28941039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: findings from a Phase IIa study.
    Takeuchi T; Tanaka Y; Close D; Godwood A; Wu CY; Saurigny D
    Mod Rheumatol; 2015 Jan; 25(1):21-30. PubMed ID: 24720551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date.
    Crotti C; Raimondo MG; Becciolini A; Biggioggero M; Favalli EG
    Drug Des Devel Ther; 2017; 11():211-223. PubMed ID: 28144129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rheumatoid arthritis: new monoclonal antibodies.
    Serio I; Tovoli F
    Drugs Today (Barc); 2018 Mar; 54(3):219-230. PubMed ID: 29771256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological therapies for rheumatoid arthritis: progress to date.
    Malviya G; Salemi S; Laganà B; Diamanti AP; D'Amelio R; Signore A
    BioDrugs; 2013 Aug; 27(4):329-45. PubMed ID: 23558378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mavrilimumab, a human monoclonal GM-CSF receptor-α antibody for the management of rheumatoid arthritis: a novel approach to therapy.
    Nair JR; Edwards SW; Moots RJ
    Expert Opin Biol Ther; 2012 Dec; 12(12):1661-8. PubMed ID: 23094973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The VICM biomarker is released from activated macrophages and inhibited by anti-GM-CSFRα-mAb treatment in rheumatoid arthritis patients.
    Mortensen JH; Guo X; De Los Reyes M; Dziegiel MH; Karsdal MA; Bay-Jensen AC; White WI
    Clin Exp Rheumatol; 2019; 37(1):73-80. PubMed ID: 30418117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid Arthritis.
    Kjelgaard-Petersen CF; Platt A; Braddock M; Jenkins MA; Musa K; Graham E; Gantzel T; Slynn G; Weinblatt ME; Karsdal MA; Thudium CS; Bay-Jensen AC
    Arthritis Rheumatol; 2018 Sep; 70(9):1419-1428. PubMed ID: 29669391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic modeling of antigen sink effect for mavrilimumab following intravenous administration in patients with rheumatoid arthritis.
    Wang B; Lau YY; Liang M; Vainshtein I; Zusmanovich M; Lu H; Magrini F; Sleeman M; Roskos L
    J Clin Pharmacol; 2012 Aug; 52(8):1150-61. PubMed ID: 21947370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis.
    Huizinga TW; Batalov A; Stoilov R; Lloyd E; Wagner T; Saurigny D; Souberbielle B; Esfandiari E
    Arthritis Res Ther; 2017 Mar; 19(1):53. PubMed ID: 28274253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary pharmacodynamics of an anti-GM-CSFRα antibody enables therapeutic dosing that limits exposure in the lung.
    Campbell J; Nys J; Eghobamien L; Cohen ES; Robinson MJ; Sleeman MA
    MAbs; 2016 Oct; 8(7):1398-1406. PubMed ID: 27560702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigational therapies targeting the granulocyte macrophage colony-stimulating factor receptor-α in rheumatoid arthritis: focus on mavrilimumab.
    Cook AD; Hamilton JA
    Ther Adv Musculoskelet Dis; 2018 Feb; 10(2):29-38. PubMed ID: 29387176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein engineering and preclinical development of a GM-CSF receptor antibody for the treatment of rheumatoid arthritis.
    Minter RR; Cohen ES; Wang B; Liang M; Vainshtein I; Rees G; Eghobamien L; Harrison P; Sims DA; Matthews C; Wilkinson T; Monk P; Drinkwater C; Fabri L; Nash A; McCourt M; Jermutus L; Roskos L; Anderson IK; Sleeman MA
    Br J Pharmacol; 2013 Jan; 168(1):200-11. PubMed ID: 22913645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.